Search Results - "Yabusaki, H."

Gastrectomy with or without omentectomy for cT3–4 gastric cancer: a multicentre cohort study by Ri, M., Nunobe, S., Honda, M., Akimoto, E., Kinoshita, T., Hori, S., Aizawa, M., Yabusaki, H., Isobe, Y., Kawakubo, H., Abe, T.

“…Background Omentectomy is performed widely for locally advanced gastric cancer to prevent disease recurrence. However, its clinical benefit is unknown. Methods…”
Get full text

An exploratory study of intraperitoneal paclitaxel combined with mFOLFOX6 for peritoneal disseminated gastric cancer patients with inadequate oral intake by Kadowaki, S., Ishigami, H., Muro, K., Yoshida, S., Hirono, Y., Tomita, T., Yabusaki, H., Kusumoto, T., Ota, M., Kodera, Y., Tsuji, Y., Hidemura, A., Hachiya, O., Oba, K., Kitayama, J.

Get full text

Molecular Biomarker Study in a Randomised Phase III Trial of Irinotecan Plus S-1 versus S-1 for Advanced Gastric Cancer (GC0301/TOP-002) by Tsuburaya, A, Sugimoto, N, Imamura, H, Nishikawa, K, Imamoto, H, Tsujinaka, T, Esaki, T, Horita, Y, Kimura, Y, Fujiya, T, Takayama, O, Oono, R, Yabusaki, H, Taguri, M, Morita, S, Yamada, Y, Tan, P, Ninomiya, M, Furukawa, H, Sasako, M

“…Abstract Aims Gastric cancer is a common and heterogeneous disease; however, global standard and biomarkers for selecting chemotherapy regimens have not been…”
Get full text

A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907) by Ando, Nobutoshi, Kato, Hoichi, Igaki, Hiroyasu, Shinoda, Masayuki, Ozawa, Soji, Shimizu, Hideaki, Nakamura, Tsutomu, Yabusaki, Hiroshi, Aoyama, Norio, Kurita, Akira, Ikeda, Kenichiro, Kanda, Tatsuo, Tsujinaka, Toshimasa, Nakamura, Kenichi, Fukuda, Haruhiko

“…Background Patients with esophageal carcinoma receiving postoperative chemotherapy showed superior disease-free survival than those receiving surgery alone in…”
Get full text

In-Medium K+ Electromagnetic Form Factor with a Symmetric Vertex in a Light Front Approach by Yabusaki, George H. S., de Melo, J. P. B. C., de Paula, Wayne, Tsushima, K., Frederico, T.

“…Using the light-front K + -Meson wave function based on a Bethe-Salpeter amplitude model for the Quark-Antiquark bound state, we study the Electromagnetic Form…”
Get full text

149P A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS by Narita, Y., Komori, A., Hironaka, S., Kawakami, H., Furuta, M., Kawakami, T., Makiyama, A., Sugiyama, K., Takegawa, N., Hirano, H., Ando, T., Matsushima, T., Chida, A., Kashiwada, T., Komoda, M., Matsumoto, T., Oda, H., Yabusaki, H., Yoshimura, K., Muro, K.

Get full text

1547P SNP discovery based on transcriptome sequencing of whole blood RNA to find predictive biomarkers for nivolumab in gastric cancer by Inagaki, C., Matoba, R., Iijuma, H., Hihara, J., Yasui, H., Tsuda, M., Suzuki, T., Makiyama, A., Yabusaki, H., Matsuyama, J., Takahashi, M., Kito, Y., Akamaru, Y., Ishiguro, A., Kawabata, R., Sakamoto, Y., Inoue, E., Ichikawa, W., Fujii, M., Sunakawa, Y.

Get full text

1549P A prospective study of circulating tumor DNA (ctDNA) genomic profiling in gastric or gastroesophageal junction (GEJ) cancer patients with recurrence after adjuvant chemotherapy: Liquid-GEAR trial by Takeda, H., Kawabata, R., Ishiguro, A., Nishina, S., Takahashi, M., Suzuki, S., Suzuki, T., Matsuyama, J., Okita, A., Miyagaki, H., Takegawa, N., Nomura, T., Kito, Y., Yabusaki, H., Negoro, Y., Makiyama, A., Nakamura, M., Takahashi, M., Sunakawa, Y.

Get full text

P-56 A multicenter prospective translational study using circulating tumor DNA to identify acquired genomic alterations in recurrent gastric or gastroesophageal junction adenocarcinoma in patients who received curative-intent treatment (Liquid-GEAR) by Takeda, H., Suzuki, T., Okita, A., Ishiguro, A., Yabusaki, H., Matsuyama, J., Takahashi, M., Takegawa, N., Fukushima, N., Nishina, S., Kawabata, R., Kito, Y., Negoro, Y., Sunakawa, Y.

Get full text

1224P Final analysis of clinical outcomes in the DELIVER trial: Observational study of nivolumab treatment in advanced gastric cancer (JACCRO GC-08) by Sunakawa, Y., Inoue, E., Sakamoto, Y., Kawabata, R., Ishiguro, A., Akamaru, Y., Kito, Y., Takahashi, M., Matsuyama, J., Yabusaki, H., Makiyama, A., Suzuki, T., Tsuda, M., Yasui, H., Kawakami, H., Nakajima, T.E., Muro, K., Matoba, R., Ichikawa, W., Fujii, M.

Get full text

1259TiP Investigator-initiated phase II study of nivolumab plus low-dose ipilimumab as first-line therapy for microsatellite instability—high advanced gastric or esophagogastric junction cancer (NO LIMIT, WJOG13320G/CA209-7W7) by Kawakami, H., Kadowaki, S., Hirata, K., Tsuda, M., Esaki, T., Sugimoto, N., Makiyama, A., Machida, N., Hirano, H., Hara, H., Kawakami, T., Okamoto, W., Yabusaki, H., Komatsu, Y., Hironaka, S., Muro, K.

Get full text

138MO Pembrolizumab (Pembro) or placebo (Pbo) plus chemotherapy (Chemo) for advanced HER2-negative gastric/gastroesophageal junction (G/GEJ) adenocarcinoma (KEYNOTE-859): Asia subgroup analysis by Oh, D-Y., Bai, Y., Ryu, M.H., Lee, J., Li, J., Luo, S., Pan, H., Qu, Y., Lu, J., Yang, L., Yasui, H., Yabusaki, H., Yen, C.J., Chan, W.W.L., Yamaguchi, K., Yeh, K-H., Yin, L., Bordia, S., Bhagia, P., Rha, S.Y.

Get full text

LBA74 Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy in locally-advanced gastric and gastroesophageal junction cancer: The phase III KEYNOTE-585 study by Shitara, K., Rha, S.Y., Wyrwicz, L.S., Oshima, T., Karaseva, N., Osipov, M., Yasui, H., Yabusaki, H., Afanasyev, S., Park, Y-K., Al-Batran, S-E., Yoshikawa, T., Yanez Weber, P.E., Di Bartolomeo, M., Lonardi, S., Fang, X., Shih, C-S., Bhagia, P., Bang, Y-J.

Get full text

O-14 Exploratory biomarker analysis of trastuzumab deruxtecan in DESTINY-Gastric01, a randomized, phase 2, multicenter, open-label study in patients with HER2-positive or -low advanced gastric or gastroesophageal junction adenocarcinoma by Shitara, K., Bang, Y., Iwasa, S., Sugimoto, N., Ryu, M., Sakai, D., Chung, H., Omuro, Y., Kawakami, H., Yabusaki, H., Sakamoto, Y., Nishina, T., Inaki, K., Kuwahara, Y., Suto, F., Sugihara, M., Saito, K., Kojima, A., Yamaguchi, K.

Get full text

SO-8 Soluble programmed cell death ligand 1 associated with clinical outcome in gastric cancer patients treated with nivolumab: Blood based biomarker analysis of DELIVER trial (JACCRO-GC08AR) by Kawakami, H., Sunakawa, Y., Inoue, E., Matoba, R., Noda, K., Sato, T., Suminaka, C., Sakamoto, Y., Kawabata, R., Ishiguro, A., Akamaru, Y., Kito, Y., Yabusaki, H., Matsuyama, J., Takahashi, M., Makiyama, A., Hayashi, H., Chamoto, K., Honjo, T., Nakagawa, K., Ichikawa, W., Fujii, M.

Get full text

128P Clinical update with plasma and tumour-based genomic analyses in expansion part of phase I study of selective FGFR inhibitor E7090 by Morizane, C., Ueno, M., Ioka, T., Tajika, M., Ikeda, M., Yamaguchi, K., Hara, H., Yabusaki, H., Miyamoto, A., Iwasa, S., Muto, M., Takashima, T., Minashi, K., Komatsu, Y., Nishina, T., Nakajima, T., Sahara, T., Funasaka, S., Yashiro, M., Furuse, J.

Get full text

1422MO Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study by Yamaguchi, K., Bang, Y-J., Iwasa, S., Sugimoto, N., Ryu, M-H., Sakai, D., Chung, H.C., Kawakami, H., Yabusaki, H., Lee, J., Saito, K., Kawaguchi, Y., Kamio, T., Kojima, A., Sugihara, M., Shitara, K.

Get full text

O-11 Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: A randomized, phase 2, multicenter, open-label study (DESTINY-Gastric01) by Yamaguchi, K., Bang, Y., Iwasa, S., Sugimoto, N., Ryu, M., Sakai, D., Chung, H., Kawakami, H., Yabusaki, H., Lee, J., Saito, K., Kawaguchi, Y., Kamio, T., Kojima, A., Sugihara, M., Shitara, K.

Get full text

O-13 Gut microbiome to predict survival time in advanced gastric cancer treated with nivolumab: The DELIVER trial (JACCRO GC-08) by Sunakawa, Y., Matoba, R., Inoue, E., Sakamoto, Y., Kawabata, R., Ishiguro, A., Akamaru, Y., Kito, Y., Takahashi, M., Matsuyama, J., Yabusaki, H., Makiyama, A., Suzuki, T., Tsuda, M., Yasui, H., Hihara, J., Takeno, A., Kawakami, H., Muro, K., Nakajima, T., Ichikawa, W., Fujii, M.

Get full text

820PInterim analysis of an observational/translational study for nivolumab treatment in advanced gastric cancer: JACCRO GC-08 (DELIVER trial) by Sunakawa, Y, Takahashi, Y, Inoue, E, Sakamoto, Y, Kawabata, R, Yabusaki, H, Matsuyama, J, Ishiguro, A, Takahashi, M, Akamaru, Y, Kito, Y, Makiyama, A, Yasui, H, Kawakami, H, Nakajima, T E, Muro, K, Matoba, R, Ichikawa, W, Fujii, M

“…Abstract Background Nivolumab (Nivo) demonstrated survival benefit in previously treated gastric cancer (GC) patients (pts), with a response rate (RR) of 11%…”
Get full text